ABT Stock Recent News
ABT LATEST HEADLINES
On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion.
The Investment Committee debate the latest Calls Of The Day.
There are many reasons to own Abbott Laboratories ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among healthcare names.
Abbott Laboratories ABT reported better-than-expected third-quarter results on Wednesday.
The healthcare stock is lagging the market this year.
This article emphasizes the importance of stock picking in today's market, where elevated valuations and sector rotations make it essential for generating returns. I've identified two dividend stocks that stand out due to their strong fundamentals and growth potential. These selections cater to income investors seeking stability. By focusing on unique opportunities, I aim to navigate the market effectively. These dividend picks combine reliable income with promising growth prospects for long-term success.
Investors bumped its shares higher following a decent, if unspectacular, earnings report.
The Investment Committee discuss some of their stocks on the move.
Abbott Laboratories (NYSE:ABT ) Q3 2024 Results Conference Call October 16, 2024 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Phil Boudreau - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Joshua Jennings - TD Cowen Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Matt Miksic - Barclays Danielle Antalffy - UBS Operator Good day, and thank you for standing by. Welcome to Abbott's Third Quarter 2024 Earnings Conference Call.
Abbott Laboratories (ABT) shares rose Wednesday, after the drug and healthcare products maker reported better-than-expected quarterly results and raised the midpoint of its profit outlook on strong demand for its medical devices.